Genetic variation in otos is associated with cisplatin-induced ototoxicity

Pharmacogenomics

Volumn 15, Issue 13, 2014, Pages 1667-1676

  Spracklen, Timothy F ^a   Whitehorn, Heather ^a   Vorster, Anna Alvera ^a   Ramma, Lebogang ^b   Dalvie, Sameera ^b   Ramesar, Rajkumar S ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

cisplatin; hearing loss; Otos; ototoxicity; South Africa

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT; OTOS PROTEIN, HUMAN; PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG MEGADOSE; ETHNICITY; EXON; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENITAL TRACT CANCER; HEAD AND NECK CANCER; HEARING IMPAIRMENT; HUMAN; INTRON; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OTOS GENE; OTOTOXICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AFRICA; URINARY TRACT CANCER; ADOLESCENT; AGED; CHEMICALLY INDUCED; GENETICS; MIDDLE AGED; PERCEPTION DEAFNESS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; GENETIC VARIATION; HEARING LOSS, SENSORINEURAL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS;

EID: 84913541016     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.112     Document Type: Article

References (36)

1. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit. Rev. Oncol. Hematol. 42(3), 317-325 (2002).
2. Santoso JT, Lucci JA, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother. Pharmacol. 52(1), 13-18 (2003).
3. Bokemeyer C, Berger CC, Hartmann JT et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Cancer 77(8), 1355-1362 (1998).
4. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J. Clin. Oncol. 23(34), 8588-8596 (2005).
5. Whitehorn H, Sibanda M, Lacerda M et al. High prevalence of cisplatin-induced ototoxicity in Cape Town. S. Afr. Med. J. 4(104) 288-291 (2014).
6. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur. J. Cancer 40(16), 2445-2451 (2004).
7. Chen WC, Jackson A, Budnick AS et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 106(4), 820-829 (2006).
8. Harris T, Peer S, Fagan JJ. Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting. J. Laryngol. Otol. 126(6), 548-551 (2012).
9. Mukherjea D, Rybak LP. Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 12(7), 1039-1050 (2011).
10. Delprat B, Boulanger A, Wang J et al. Downregulation of otospiralin, a novel inner ear protein, causes hair cell degeneration and deafness. J. Neurosci. 22(5), 1718-1725 (2002).
11. Delprat B, Ruel J, Guitton MJ et al. Deafness and cochlear fibrocyte alterations in mice deficient for the inner ear protein otospiralin. Mol. Cell. Biol. 25(2), 847-853 (2005).
12. Caravelli A, Pianese L, Saulino C et al. Down-regulation of otospiralin mRNA in response to acoustic stress in guinea pig. Hear. Res. 198(1-2), 36-40 (2004).
13. Zhuo XL, Wang Y, Zhuo WL, Zhang YS, Wei YJ, Zhang XY. Adenoviral-mediated up-regulation of Otos, a novel specific cochlear gene, decreases cisplatin-induced apoptosis of cultured spiral ligament fibrocytes via MAPK/mitochondrial pathway. Toxicology 248(1), 33-38 (2008).
14. Waissbluth S, Pitaro J, Daniel SJ. Gene therapy for cisplatin-induced ototoxicity: a systematic review of in vitro and experimental animal studies. Otol. Neurotol. 33(3), 302-310 (2012).
15. Tishkoff SA, Williams SM. Genetic analysis of African populations: human evolution and complex disease. Nat. Rev. Genet. 3(8), 611-621 (2002).
16. World Medical Association. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(2), 2191-2194.
17. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. American Speech-Language-Hearing Association. 36, 11-19 (1994). www.asha.org/policy/GL1994-00003.htm
18. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J. Clin. Oncol. 28(10), 1788-1795 (2010).
19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl. Acids Res. 16(3), 1215 (1988).
20. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT1999. Nucl. Acids Symp. 41, 95-98 (1999).
21. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15(2), 97-98 (2005).
22. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet. 74(4), 765-769 (2004).
23. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19(1), 149-150 (2003).
24. Sakamoto M, Kaga K, Kamio T. Extended high-frequency ototoxicity induced by the first administration of cisplatin. Otolaryngol. Head Neck Surg. 122(6), 828-833 (2000).
25. Sprauten M, Darrah TH, Peterson DR et al. Impact of long-term serum platinum concentrations on neuro-and ototoxicity in cisplatin-treated survivors of testicular cancer. J. Clin. Oncol. 30(3), 300-307 (2012).
26. Dolan ME, Newbold KG, Nagasubramanian R et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64, 4353-4356 (2004).
27. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 25(6), 708-714 (2007).
28. Riedemann L, Lanvers C, Deuster D et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J. 8(1), 23-28 (2008).
29. Ross CJ, Katzov-Eckert H, Dubé MP et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41(12), 1345-1349 (2009).
30. Pussegoda K, Ross CJ, Visscher H et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 94(2), 243-251 (2013).
31. Caronia D, Patinõ-Garciá A, Milne RL et al. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J. 9(5), 347-353 (2009).
32. Choeyprasert W, Sawangpanich R, Lertsukprasert K et al. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. J. Pediatr. Hematol. Oncol. 35(4), 138-143 (2013).
33. Yang JJ, Lim JYS, Huang J et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin. Pharmacol. Ther. 94(2), 252-259 (2013).
34. Whitehorn H. Pharmacogenetics: investigating the genetic basis of cisplatin-induced ototoxicity in adult South African cancer patients. MSc (Med) thesis, University of Cape Town, South Africa (2013).
35. Clerici WJ, Hensley K, DiMartino DL, Butterfield DA. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear. Res. 98(1-2), 116-124 (1996).
36. Decourt B, Hillman D, Bouleau Y, Dulon D, Hafidi A. Is otospiralin inner ear specific? Evidence for its expression in mouse brain. Int. J. Dev. Neurosci. 27(1), 87-96 (2009).